Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH

Francesco Blasi, Javier Garau, Jesús Medina, Marco Ávila, Kyle McBride, Helmut Ostermann, REACH study group, Francesco Blasi, Javier Garau, Jesús Medina, Marco Ávila, Kyle McBride, Helmut Ostermann, REACH study group

Abstract

Background: Data describing real-life management and treatment of community-acquired pneumonia (CAP) in Europe are limited. REACH (http://NCT01293435) was a retrospective, observational study collecting data on the management of EU patients hospitalized with CAP.

Methods: Patients were aged ≥18 years, hospitalized with CAP between March 2010 and February 2011, and requiring in-hospital treatment with intravenous antibiotics. An electronic Case Report Form was used to collect patient, disease and treatment variables, including type of CAP, medical history, treatment setting, antibiotics administered and clinical outcomes.

Results: Patients (N = 2,039) were recruited from 128 centres in ten EU countries (Belgium, France, Germany, Greece, Italy, the Netherlands, Portugal, Spain, Turkey, UK). The majority of patients were aged ≥65 years (56.4%) and had CAP only (78.8%). Initial antibiotic treatment modification occurred in 28.9% of patients and was more likely in certain groups (patients with comorbidities; more severely ill patients; patients with healthcare-associated pneumonia, immunosuppression or recurrent episodes of CAP). Streamlining (de-escalation) of therapy occurred in 5.1% of patients. Mean length of hospital stay was 12.6 days and overall mortality was 7.2%.

Conclusion: These data provide a current overview of clinical practice in patients with CAP in EU hospitals, revealing high rates of initial antibiotic treatment modification. The findings may precipitate reassessment of optimal management regimens for hospitalized CAP patients.

Figures

Figure 1
Figure 1
Patient flow.
Figure 2
Figure 2
Distribution of patients according to time to clinical stability.

References

    1. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl. 2002;36:20s–27s.
    1. Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis. 2012;31:33–47. doi: 10.1007/s10096-011-1272-4.
    1. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med. 2009;30:127–135. doi: 10.1055/s-0029-1202941.
    1. Capelastegui A, Espana PP, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, Esteban C, Altube L, Gorordo I, Quintana JM. Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care. J Infect. 2010;61:364–371. doi: 10.1016/j.jinf.2010.07.015.
    1. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ. Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1–E59.
    1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
    1. Martinez R, Reyes S, Lorenzo MJ, Menendez R. Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med. 2009;30:172–178. doi: 10.1055/s-0029-1202936.
    1. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):IV1–IV64.
    1. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2010;67:71–79.
    1. Aspa J, Rajas O, de Castro FR. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother. 2008;9:229–241. doi: 10.1517/14656566.9.2.229.
    1. Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, Schultze-Werninghaus G. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128:2238–2246. doi: 10.1378/chest.128.4.2238.
    1. World Health Organization. International Classification of Diseases (ICD) 10th Revision (2007 version) Geneva, Switzerland: World Health Organization; 2007.
    1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250. doi: 10.1056/NEJM199701233360402.
    1. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382. doi: 10.1136/thorax.58.5.377.
    1. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, Singer DE. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279:1452–1457. doi: 10.1001/jama.279.18.1452.
    1. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii3–iii9.
    1. Garau J, Baquero F, Perez-Trallero E, Perez JL, Martin-Sanchez AM, Garcia-Rey C, Martin-Herrero JE, Dal-Ré R. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect. 2008;14:322–329. doi: 10.1111/j.1469-0691.2007.01915.x.
    1. Blasi F, Iori I, Bulfoni A, Corrao S, Costantino S, Legnani D. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J. 2008;32:902–910. doi: 10.1183/09031936.00092607.
    1. Garcia-Vidal C, Carratala J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med. 2009;30:154–160. doi: 10.1055/s-0029-1202934.
    1. Stralin K, Olcen P, Tornqvist E, Holmberg H. Definite, probable, and possible bacterial aetiologies of community-acquired pneumonia at different CRB-65 scores. Scand J Infect Dis. 2010;42:426–434. doi: 10.3109/00365540903552353.
    1. Garcia-Vidal C, Carratala J, Fernandez-Sabe N, Dorca J, Verdaguer R, Manresa F, Gudiol F. Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clin Microbiol Infect. 2009;15:1033–1038. doi: 10.1111/j.1469-0691.2009.02918.x.
    1. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309–316. doi: 10.1016/j.rmed.2008.08.006.
    1. Gutierrez F, Masia M, Rodriguez JC, Mirete C, Soldan B, Padilla S, Hernandez I, De Ory F, Royo G, Hidalgo AM. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect. 2005;11:788–800. doi: 10.1111/j.1469-0691.2005.01226.x.
    1. Hedlund J, Ortqvist A, Ahlqvist T, Augustinsson A, Beckman H, Blanck C, Burman LA, Claesson B, Qvarfordt I, Elbel E, Erntell M, Follin P, Goscinski G, Holmberg H, Hofer M, Jorup C, Lidman C, Lindhusen E, Rensfeldt G, Rosenkvist E, Stenlund G, Stalberg A, Verngren K, Vig I, Wendahl S. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis. 2002;34:887–892. doi: 10.1080/0036554021000026965.
    1. Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angrill J, Garcia E, Mensa J, Niederman MS, Torres A. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest. 2007;132:515–522. doi: 10.1378/chest.07-0306.
    1. Tudose C, Bumbacea D, Bogdan M. Antibiotic resistance of S. pneumoniae and H. influenzae strains isolated from patients with community acquired respiratory tract infections. BACTRO multicenter, multidisciplinary study. Pneumologia. 2011;60:30–35.
    1. Valles X, Marcos A, Pinart M, Piner R, Marco F, Mensa JM, Torres A. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest. 2006;130:800–806. doi: 10.1378/chest.130.3.800.
    1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–1754. doi: 10.1164/ajrccm.163.7.at1010.
    1. Dambrava PG, Torres A, Valles X, Mensa J, Marcos MA, Penarroja G, Camps M, Estruch R, Sanchez M, Menendez R, Niederman MS. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J. 2008;32:892–901. doi: 10.1183/09031936.00163407.
    1. Orrick JJ, Segal R, Johns TE, Russell W, Wang F, Yin DD. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics. 2004;22:751–757. doi: 10.2165/00019053-200422110-00005.
    1. Merchant S, Mullins CD, Shih YC. Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther. 2003;25:593–610. doi: 10.1016/S0149-2918(03)80099-1.
    1. Brown PD. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care? Pharmacoeconomics. 2004;22:413–420. doi: 10.2165/00019053-200422070-00001.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться